TPI-1

SKU: orb1303509

Description

TPI-1

Research Area

Metabolism Research

Key Properties

• CAS Number: 79756-69-7
• MW: 253.08
• Purity: 98.25% (May vary between batches)
• Formula: C₁₂H₆Cl₂O₂
• SMILES: Clc1ccc(Cl)c(c1)C1=CC(=O)C=CC1=O
• Target: Glucocorticoid Receptor,Phosphatase
• Solubility: DMSO:45 mg/mL (177.81 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (7.9 mM)

Bioactivity

• Target IC50:
  SHP1:40 nM.
• In Vivo:
  TPI-1 effectively suppresses the growth of B16 melanoma tumors in mice through a mechanism reliant on T cells when administered orally at tolerable doses, yet it demonstrates minimal impact on B16 cell proliferation in vitro. Additionally, TPI-1 enhances the levels of pLck-pY394 and IFNγ+ cells in mice, further contributing to its anti-tumor activity. Notably, TPI-1 also restricts B16 tumor expansion and extends the survival of mice bearing tumors when given as a subcutaneously tolerated agent.
• In Vitro:
  SHP-1 has been identified as a promising target for cancer therapy. TPI-1, starting at an effective concentration of 10 ng/mL, selectively enhances the phosphorylation of SHP-1 substrates (notably pLck-pY394) in Jurkat T cells, without significantly affecting pERK1/2 or pLck-pY505 levels. Moreover, TPI-1 promotes the induction of IFNγ+ cells both in mouse spleen and human peripheral blood, demonstrating its potential selectivity and therapeutic efficacy in a cellular context.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

GlucocorticoidReceptor, Glucocorticoid Receptor, Inhibitor, inhibit, TPI 1, TPI1, TPI-1, Phosphatase, recombinant SHP-1

Compound Identifiers

PubChem CID

948589